Oblique parallel incisions in 25G surgery improves healing

Article

Performing 25-gauge pars plana vitrectomy with oblique parallel incisions rather than with standard straight incisions, may allow for more complete postoperative wound sealing.

Performing 25-gauge pars plana vitrectomy with oblique parallel incisions rather than with standard straight incisions, may allow for more complete postoperative wound sealing, according to a report published in the September issue of Graefe's Archive for Clinical and Experimental Ophthalmology.

Stanislao Rizzo and colleagues from the Santa Chiara Hospital, Pisa, Italy enrolled 45 patients with macular holes. In 15 eyes, operations were carried out using oblique parallel insertion, in a further 15, oblique perpendicular insertions were used, and the remaining 15 received straight incisions (SI). Each patient underwent ultrasound biomicroscopy (UBM) examinations, one day, one week and one month postoperatively.

Oblique parallel insertions healed immediately following removal of the 25-gauge cannula. At one day postoperatively, all sclerotomies were well-healed with the internal wound lips showing excellent apposition. In addition, 39 sclerotomies were undetectable by UBM and six were only just observable.

In the oblique perpendicular insertion group, the incisions also healed immediately and all sclerotomies were well-healed by one day postoperatively. However, minimal gape was visible on UBM. Three eyes also showed peripheral cilio-choroidal detachment at one day postoperatively — this was resolved in all cases by seven days follow-up.

In the straight incision group, 10 cases of conjunctival blebs developed. Of these, seven required air-gas refilling and three required suturing of the sclerotomies. By one day postoperatively, five subjects developed hypotony and UBM demonstrated significant gaps in all sites.

The authors concluded that oblique parallel incisions allow for better postoperative wound sealing.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.